NCT03971110 is a Phase 4 clinical trial of Zoladex and Casodex in Advanced Prostate Cancer, sponsored by AstraZeneca.

Who is sponsoring NCT03971110?

NCT03971110 is sponsored by AstraZeneca.

What drugs are being tested in NCT03971110?

Interventions in NCT03971110: Zoladex and Casodex.

What condition does NCT03971110 study?

NCT03971110 studies Advanced Prostate Cancer.

Is NCT03971110 still recruiting?

NCT03971110 is currently terminated. Last updated 16 December 2022.

Last reviewed 2022-12-16 · How we verify

NCT03971110

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of Neoadjuvant Hormone Therapy in Patient With Advanced Prostate Cancer Undergoing Radical Prostatectomy.

Terminated Phase 4 Last updated 16 December 2022

What this trial tests

Phase 4 trial testing Zoladex and Casodex in Advanced Prostate Cancer in 9 participants. Terminated before completion.

Timeline

28 January 2021

Primary endpoint
9 November 2022

9 November 2022

Quick facts

Lead sponsor	AstraZeneca
Phase	Phase 4
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	9
Start date	28 January 2021
Primary completion	9 November 2022
Estimated completion	9 November 2022
Sites	15 locations across China

Drugs / interventions tested

Zoladex and Casodex — full drug profile →

Conditions studied

Advanced Prostate Cancer — all drugs for Advanced Prostate Cancer →

Sponsor

AstraZeneca — full company profile →

Who can join

Eligibility, any sex, with Advanced Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is A Multi-centre, Single-arm, Prospective, Interventional Study to Assess Efficacy and Safety of Neoadjuvant Hormone Therapy using Zoladex (Goserelin) and Casodex (Bicalutamide) in Patients with Advanced Prostate Cancer Undergoing Radical Prostatectomy, to assess the efficacy by resectability rate of neoadjuvant hormone therapy (NHT) in subjects with advanced prostate cancer.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Targeting signaling pathways in prostate cancer: mechanisms and clinical trials.
He Y, Xu W, Xiao YT, Huang H, et al · · 2022 · cited 192× · PMID 35750683 · DOI 10.1038/s41392-022-01042-7

Verify or expand the search:

Other recruiting trials for Advanced Prostate Cancer

Currently open trials in the same condition.

NCT06769425 — HS-10502 Combination Treatment in Patients With Advanced Solid Tumors · Phase 1 · recruiting
NCT06335914 — Dual PSMA and FDG PET Imaging for Patients With Advanced Prostate Cancer · NA · recruiting
NCT06463457 — Comeback From Long coursE Androgen Deprivation Therapy (ADT) With RElugolix and Darolutamide (CLEARED) · Phase 2 · active not recruiting
NCT06866782 — European Registry of Next Generation Imaging in Advanced Prostate Cancer · recruiting
NCT06369246 — PRORAD-5 PROstate RADiation in 5 Fractions: Phase II Five Fraction Radiotherapy for Patients With Advanced Prostate Canc · Phase 1 · recruiting

Other AstraZeneca trials

Trials by the same sponsor.

NCT06998095 — Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea · not yet recruiting
NCT07431775 — Saphnelo Use in Females of Child-bearing Potential · not yet recruiting
NCT07516184 — Explore the Diagnostic Value of Bronchodilation Test With Portable Oscillometry in Asthma Diagnosis · NA · not yet recruiting
NCT07279935 — Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resec · Phase 4 · not yet recruiting
NCT07279948 — A Single-arm Observational Study to Characterize the Demographic, Clinical Features and Outcomes of a Brazilian Cohort o · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03971110 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by AstraZeneca
Last refreshed: 16 December 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03971110.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing